Accordingly, disrupting the S1P gradient by 2-acetyl-4-tetrahydroxybutylimidazole, an inhibitor of the S1P lyase, led to lymphopenia and inhibited T cell egress from the thymus, which was mediated by a downregulation of surface S1P1 [49]. The gene discussed is S1PR1; the disease is lymphopenia.